[
  {
    "ts": "2026-02-03T00:29:29+00:00",
    "headline": "Gilead Sciences, Inc. (GILD): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Gilead Sciences, Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $141.95 as of January 30th. GILD’s trailing and forward P/E were 21.60 and 15.87 respectively according to Yahoo Finance. Gilead Sciences (GILD), historically […]",
    "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-bull-002929279.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "341fde0b-140d-3ba2-8fd3-0f30370a1a40",
      "content": {
        "id": "341fde0b-140d-3ba2-8fd3-0f30370a1a40",
        "contentType": "STORY",
        "title": "Gilead Sciences, Inc. (GILD): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Gilead Sciences, Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $141.95 as of January 30th. GILD’s trailing and forward P/E were 21.60 and 15.87 respectively according to Yahoo Finance. Gilead Sciences (GILD), historically […]",
        "pubDate": "2026-02-03T00:29:29Z",
        "displayTime": "2026-02-03T00:29:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/97c55cc862e51e1536055674940eb625",
          "originalWidth": 1000,
          "originalHeight": 800,
          "caption": "5 Countries With Highest Rates of AIDS",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gyv.qUWrWDbJVH31YAdquQ--~B/aD04MDA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/97c55cc862e51e1536055674940eb625.cf.webp",
              "width": 1000,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XFv35.05vo7Qfn9858VgdQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/97c55cc862e51e1536055674940eb625.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-bull-002929279.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-bull-002929279.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "RPTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-03T06:10:52+00:00",
    "headline": "Gilead Sciences Oncology Push Gains Traction With Trodelvy Keytruda Results",
    "summary": "Gilead Sciences reported positive Phase 3 results for Trodelvy combined with Keytruda in first-line PD-L1+ metastatic triple-negative breast cancer. The data, published in The New England Journal of Medicine, point to meaningful clinical benefits in this hard-to-treat setting. Gilead also entered a licensing agreement with Repare Therapeutics to expand its DNA-repair-targeted oncology pipeline. These developments highlight Gilead's increased focus on oncology alongside its established...",
    "url": "https://finance.yahoo.com/news/gilead-sciences-oncology-push-gains-061052164.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "b4bc7a41-515a-3318-8c97-5c4a9c6cbf33",
      "content": {
        "id": "b4bc7a41-515a-3318-8c97-5c4a9c6cbf33",
        "contentType": "STORY",
        "title": "Gilead Sciences Oncology Push Gains Traction With Trodelvy Keytruda Results",
        "description": "",
        "summary": "Gilead Sciences reported positive Phase 3 results for Trodelvy combined with Keytruda in first-line PD-L1+ metastatic triple-negative breast cancer. The data, published in The New England Journal of Medicine, point to meaningful clinical benefits in this hard-to-treat setting. Gilead also entered a licensing agreement with Repare Therapeutics to expand its DNA-repair-targeted oncology pipeline. These developments highlight Gilead's increased focus on oncology alongside its established...",
        "pubDate": "2026-02-03T06:10:52Z",
        "displayTime": "2026-02-03T06:10:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HAEiJmFsYXJTRBPxnneP6w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXB9F2qU7k4qk3_k1DQd9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-oncology-push-gains-061052164.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-oncology-push-gains-061052164.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "RPTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]